Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.
Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, Wiemers T, Weidner H, Kreuz M, Schassberger T, Kossmann J, Mangold M, Furst D, Fischer L, Baber R, Heyn S, Wang SY, Bach E, Hoffmann S, Metzeler KH, Herlling M, Jentzsch M, Franke GN, Kohl U, Friedrich M, Boldt A, Reiche K, Platzbecker U, Vucinic V, Merz M.
Fandrei D, et al. Among authors: baber r.
Blood Cancer Discov. 2024 Oct 23. doi: 10.1158/2643-3230.BCD-24-0118. Online ahead of print.
Blood Cancer Discov. 2024.
PMID: 39441177